Almac's £500M Capital Programme Delivers Fifth Consecutive Year of Growth as CDMO Market Tightens

Almac Group posted record financial results for fiscal year 2025, with revenue reaching £1.1 billion and pre-tax profit climbing 16% to £138.9 million. The contract development and manufacturing organization credited its ongoing £500 million-plus capital investment programme, now in its fifth year, with enabling the expansion.

Financial Performance

Revenue grew £71.9 million year-over-year, a 7% increase from £1.0281 billion in 2024. Pre-tax profit rose to £138.9 million from £119.3 million. The profit margin improvement to approximately 12.6% from 11.6% suggests operational use is kicking in as the capital programme matures. That's notable because Almac reinvests all profits back into the business rather than distributing to shareholders, meaning the growth is self-funded.

"These results reflect another successful year for Almac and demonstrate the resilience of our long-term growth strategy in a changing global environment." — Alan Armstrong, Chairman and CEO

Capital Programme Breakdown

The investment strategy targets five operational areas: diagnostic and pharmaceutical development and manufacturing, clinical production and distribution, commercial manufacturing and packaging, global cold-chain infrastructure, and analytical services. The company also allocated funds for campus improvements.

The cold-chain investment deserves attention. Gene therapies, biologics, and temperature-sensitive oncology drugs require specialized handling and storage infrastructure. Building that capacity isn't cheap, and competitors who haven't made similar investments may struggle to compete for these higher-margin contracts.

Workforce Scaling

Headcount grew 6% to more than 7,900 employees globally. Since launching the capital programme in November 2021, Almac added more than 2,000 positions, with over half created in Northern Ireland. That geographic concentration suggests the company is building on existing operational expertise rather than dispersing capabilities across multiple sites.

Manufacturing at this scale requires skilled technicians, quality assurance personnel, and process engineers. The question is whether that hiring pace is sustainable or if it'll create training bottlenecks.

Manufacturing Output

The company supported development and commercial supply of hundreds of drugs across more than 20 therapeutic areas, including oncology, cardiology, immunology, gene therapy, and neurology. These are high-complexity product categories with demanding regulatory requirements.

The gene therapy segment is particularly capital-intensive. Viral vector manufacturing requires separate facilities, dedicated equipment, and specialized personnel. If Almac is building capacity in this space, the returns won't show up immediately in revenue figures but could drive margins in future years.

The CDMO Market Context

Contract pharmaceutical manufacturing is consolidating. Large pharmaceutical companies are outsourcing more production to control costs, and smaller biotech firms lack internal manufacturing capability entirely. That demand environment supports Almac's growth strategy, but the company faces pressure from competitors like Lonza, Catalent, and Samsung Biologics.

Almac's bet on continuous reinvestment is reasonable for a privately held company with a long-term horizon. The 16% profit growth shows the model works, at least for now. The risk is that aggressive capacity expansion ahead of demand could squeeze margins if growth slows.

The company will need to demonstrate that its expanded manufacturing footprint translates into contract wins. Headcount and revenue growth mean little if capacity utilization lags.

M4S TAKE

My take: capacity expansions signal confidence, but the real question is whether demand justifies the spend. I watch for follow-up announcements about utilization rates or new contracts. Without those, this is just capital allocation.

Simon McLoughlin